This article was originally published in Pharmaceutical Approvals Monthly
Abbott's lead project, TNF-alpha inhibitor Humira (adalimumab, D2E7), clears FDA Dec. 31 for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatics. Abbott is highlighting convenience of once-weekly dosing, efficacy in reducing structural joint damage and price to encourage switching RA patients from Amgen/Wyeth's Enbrel (etanercept) and J&J's Remicade (infliximab). Enbrel and Remicade carry more indications; Abbott plans to begin filing for five additional indications in 2004. Supply of the biologic is adequate, Abbott say
You may also be interested in...
Abbott has kicked off its planned label expansion program for Humira with an Oct. 1 filing for an improved physical function claim in rheumatoid arthritis.
Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
Tyto Care’s remote monitoring and telehealth platform has seen rising demand since the start of the pandemic and the company continues to expand. This week, it announced it raised $50m in a series D financing round. See what Dedi Gilad, CEO of Tyto Care, said about it here.